Compare stocks

Camurus AB is a biopharmaceutical company headquartered in Lund, Sweden, specializing in the development of innovative pharmaceuticals for the treatment of serious and chronic diseases. The company's core offerings focus on proprietary drug delivery technologies, including FluidCrystal® technology, which enhances the therapeutic benefits and delivery of active ingredients. Camurus concentrates its efforts on areas such as addiction treatment, pain management, and oncology, aiming to improve patient outcomes through advanced formulations. The company operates in several international markets, leveraging strategic partnerships and a focused product pipeline to maintain its position within the biopharmaceutical industry. Its operations are characterized by a strong emphasis on research and development to sustain and expand its portfolio.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.